Our results suggest an increasing trend in testing rate in the US over the study period from 68.3% in 2016 to 87.7% in 2018, indicating increased awareness of biomarker targeted therapies among oncologists.
← all excerpts
Treatment patterns and real-world clinical outcomes in patients with advanced endometrial cancer that are non-microsatellite instability high (non-MSI-high) or mismatch repair proficient (pMMR) in the United States.
1
—
—